Menu
ncarol.com
  • Home
  • Education
  • Health
  • Technology
  • Books
  • Entertainment
  • Real Estate
  • Music
  • Financial
ncarol.com

New Labcorp Test Report Helps Identify Insect Stings and Improve Therapy Decisions to Combat Allergic Reactions
ncarol.com/10182743

Trending...
  • UK Financial Ltd Launches UKFL Premier One as Its Official Broadcast Channel for Premium Content, Podcasts & Independent Expert Analysis
  • Dual-Engine Growth Strategy Unleashed Targeting a $9.1B Market and the Exploding AI Biotech Revolution: KALA BIO (N A S D A Q: KALA)
  • GitKraken Desktop 12.0 Introduces Agent Mode: Gives Developers Ultimate Control & Visualization While Scaling Parallel Agent Workflows
Download
  • Full Size
  • Small
  • Preview
  • Thumbnail

Photo courtesy of Labcorp
  • Photo courtesy of Labcorp
    • Full Size
    • Small
    • Preview
    • Thumbnail

    • Full Size
    • Small
    • Preview
    • Thumbnail


BURLINGTON, N.C.--(BUSINESS WIRE)--Nearly 10 million people in the United States have a history of systemic or anaphylactic reaction to insect stings, with the risk of a severe and potentially life-threatening allergic reaction. To help facilitate more effective venom therapy, Labcorp (NYSE: LH), a leading global life sciences company, has launched its unique Labcorp Clinical Decision Support (CDS) interpretative test report for its Stinging Insect Component-Specific IgE Test that provides allergen test interpretation and treatment suggestions.

More on ncarol.com
  • HarryPotterObamaSonic10Inu Celebrates World Record 1,000+ Days Livestream with Record-Breaking Merchandise Launch
  • Igniting High-Growth Expansion as Electrification Strategy and Infrastructure Dominance Converge; 88% Revenue Growth (N Y S E: MWG)
  • Appliance EMT Presents Multi-Thousand Dollar Donation to Kids Motel Ministry to Support Local Families
  • New Report Reveals Plane Crashes Are Not Where You'd Think
  • Whiteside & Goldberg Investigating Claims on Behalf of Victims in TJ Maxx Hidden Camera Incident in Machesney Park, Illinois

"Labcorp is the only reference laboratory to offer stinging insect (venom) component testing," said Dr. Andre Valcour, vice president and laboratory director of Labcorp Diagnostic's esoteric testing unit. "The launch of this new interpretative report is another example of how Labcorp continues to provide clinical expertise and value to providers and patients by identifying specific insect species for therapy and offering guidance on successful venom immunotherapy."

Over half of stinging insect patients test positive for allergic reactions to both honeybee and yellow jacket (wasp) venom. Labcorp's Stinging Insect Component-Specific IgE Testing helps identify the specific venom to which the patient is allergic and provides a more precise diagnosis to support venom immunotherapy. Venom-specific immunotherapy (VIT) is an effective treatment for venom allergy that can help protect against future reactions, minimize side effects and lower treatment costs.

The Labcorp CDS interpretative venom allergy report expands on prior reporting to provide report interpretation and uses current Allergy Practice Parameters, which are sponsored by the American Academy of Allergy, Asthma and Immunology and the American College of Allergy, Asthma and Immunology, to offer treatment suggestions. Dr. David Golden, a leading expert on stinging insect allergies and former chair of the Stinging Insect Hypersensitivity Practice Parameter Update workgroup, collaborated with Labcorp to establish this vital report.

"It is very important to identify the specific insect species for effective therapy," said Dr. Golden, an associate professor of medicine at Johns Hopkins University and the allergy division chief at both Sinai Hospital and Franklin Square Hospital in Baltimore, Maryland. "Venom component testing is valuable as it can differentiate between species-specific sensitization and cross-reactivity, fine tune venom diagnosis, and help physicians determine the most appropriate and cost-effective treatment plans for patients."

The Labcorp CDS interpretive report follows the Practice Parameters and provides physicians comprehensive insight on diagnostic marker interpretation, treatment suggestions and guidance for managing venom and stinging insect therapy. To learn about the Practice Parameters, visit their website.

More on ncarol.com
  • "Fearless and Free": Long Beach Pride 2026 Celebrates Resilience, Family, and Multicultural Connection
  • 50 Years of Small Business Wisdom, Supercharged by AI: Shelly Berman Launches The Business Health Check
  • Deborah E. Jones Releases Emotional Sovereignty, a Book on Emotional Awareness and Self-Regulation
  • Finding the Best Lawyer: What Really Matters When Your Case Is on the Line
  • The New World of Freight Brokering with AI

About Labcorp

Labcorp is a leading global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. Through our unparalleled diagnostics and drug development capabilities, we provide insights and accelerate innovations to improve health and improve lives. With over 75,000 employees, we serve clients in more than 100 countries. Labcorp (NYSE: LH) reported revenue of $16 billion in FY2021. Learn more about us at www.Labcorp.com or follow us on LinkedIn and Twitter @Labcorp.

Contacts

Labcorp Contacts:


Media: Christopher Allman-Bradshaw – 336-436-8263
Media@Labcorp.com

Investors: Chas Cook – 336-436-5076
Investor@Labcorp.com

0) { // Create container for hi-res image jQuery('#bw-release-hires').append('
'); }; }); ]]>

Contacts

Labcorp Contacts:


Media: Christopher Allman-Bradshaw – 336-436-8263
Media@Labcorp.com

Investors: Chas Cook – 336-436-5076
Investor@Labcorp.com
Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on ncarol.com
  • New research identifies The Discovery Gap: Seven in 10 Americans say travel is no longer just about getting away
  • PropAccount.com Adds Equities to Its Multi-Asset Prop Firm Platform, Opening the Door to the World's Largest Trading Market
  • Ailias Launches Global Partner Programme for AI-Powered Conversational Digital Humans in Events and Experiences
  • Village People Headline "Rock The Rainbow" Phuket Pride Finale 2026
  • SilverBow Strategies Launches RFPArchon™, the First Product in Its Artemis AI Solutions™ Suite
  • New from Regal House Publishing, The Unfinished Business, its tricky inheriting a ghost-busting firm
  • Sawasdee Anime Launches Animenture: A Gamified SNS Connecting Global Fans to 2,000+ Anime Sites
  • "LOOK UP CAFE TOKYO SKYTREE" to Open on May 22, 2026 on the 5th floor of TOKYO SKYTREE®. This Date also Marks TOKYO SKYTREE's 14th Anniversary
  • "Rehabilitative Prison Program Compromised by Alleged Staff Misconduct, Whistleblower Claims"
  • Creator Space LA brings together industry leaders for an immersive AI showcase, demonstrations, and film hackathon
  • The Hardest Part of Building an App Isn't Starting - It's Finishing
  • Uxur Taxi Unveils Luxury 3,000‑Mile Private Driver Service for Nationwide Travel
  • Colorfront Launches New Mac App For Creating Apple Immersive Video
  • Michele Mundy's "Divinely Tailored" Gains Momentum
  • Evermore Bliss Launches AI Wedding Speech Writer to Help Users Create Personalized, Heartfelt Toasts
  • Keenethics enters the ChatGPT Apps ecosystem as a new growth opportunity for businesses
  • Spring Into Your New Home at Heritage at South Brunswick
  • Justin Fairfax Dies in Apparent Murder Suicide
  • UK Financial Ltd Launches UKFL Premier One as Its Official Broadcast Channel for Premium Content, Podcasts & Independent Expert Analysis
  • HarryPotterObamaSonic10Inu (Ticker: BITCOIN) Is the Best Cryptocurrency in Global History
_catLbl0 _catLbl1

Popular on ncarol.com

  • Registered Nurse Launches Healthcare Wealth Strategy Practice for Healthcare Professionals - 380
  • Homeowner Prep Announces Strategic Language Shift: Replacing "Renters" with "Future Homeowners" to Inspire Wealth-Building Mindsets - 149
  • Larry R. Wasion Highlights Jump Gate I: Time Chair. The Opening Novel in His Expansive Science Fiction Series
  • UK Financial Ltd Launches UKFL Premier One as Its Official Broadcast Channel for Premium Content, Podcasts & Independent Expert Analysis
  • LiposoMore™ Redefines Bioavailability: Joyful Nutritional Launches High-Performance Liposomal Vitamin C and Iron for the Global Supplement Market
  • Sycor Introduces Spring Release 2026 of Sycor.Rental with AI-Driven Innovations and Enhanced Service Processes
  • Rhealize Strategic Talent Advisory Co-Founder Dona Baker to Speak at DisruptHR YEG 15.0 in Edmonton on Hiring Innovation
  • UK Financial Ltd Tokenized LTNS 1, A $1.1 T Asset-Backed ERC-3643 Security Token with 11 On-Chain Contracts Verifying, Compliant Real-World Value
  • Pacific Emblem Company Launches "Happy 250th Birthday America" Collection and Proud Supporter of the Gary Sinise Foundation
  • Dual-Engine Growth Strategy Unleashed Targeting a $9.1B Market and the Exploding AI Biotech Revolution: KALA BIO (N A S D A Q: KALA)

Similar on ncarol.com

  • Apple Rock Open House Offers Behind-the-Scenes Look at Exhibit Production
  • $112 Million Contract Backlog for Cycurion (N A S D A Q: CYCU) Enters Hyper-Growth Phase With, Strategic Acquisitions, & Exploding AI Cybersecurity
  • HarryPotterObamaSonic10Inu Celebrates World Record 1,000+ Days Livestream with Record-Breaking Merchandise Launch
  • Igniting High-Growth Expansion as Electrification Strategy and Infrastructure Dominance Converge; 88% Revenue Growth (N Y S E: MWG)
  • Appliance EMT Presents Multi-Thousand Dollar Donation to Kids Motel Ministry to Support Local Families
  • 50 Years of Small Business Wisdom, Supercharged by AI: Shelly Berman Launches The Business Health Check
  • Deborah E. Jones Releases Emotional Sovereignty, a Book on Emotional Awareness and Self-Regulation
  • The New World of Freight Brokering with AI
  • As Fluoride Debate Grips the Nation, Americans Turn to Whole-House Fluoride Filters for Answers
  • Presidential Acceleration of Psychedelic Therapies Enters a Defining Moment as Federal Policy, FDA Alignment & Breakthrough Neurotechnology Converge
Copyright © 2026 ncarol.com | Contact Us | Privacy Policy | Terms of Service | Contribute